ENEA 2026
Effect of CAM2029 on long-term biochemical and symptom control in patients with acromegaly and insulin-like growth factor I (IGF-I) ≤2× upper limit of normal (ULN) grouped by prior injectable somatostatin receptor ligand (SRL) dose
Click the material you wish to view
